Lung cancer remains the leading cause of cancer-related mortality worldwide, with non-small-cell lung cancer (NSCLC) accounting for approximately 85% of cases [1]. Lung adenocarcinoma is the most common histological subtype of NSCLC and frequently harbors actionable driver alterations. KRAS mutations...
Jinfang Medicine-B (02595) announced that GFH375 has entered a Phase II study for first-line treatment of advanced non-small cell lung cancer (NSCLC) with KRAS G12D mutations. The study includes three treatment regimens: monotherapy, combination with an EGFR monoclonal antibody (cetuximab),...
“All patients who were response evaluable and had at least one post-baseline scan exhibited tumor shrinkage, and there were no patients that exhibited disease progression as their best overall response to treatment.” Ferdinandos Skoulidis, MD, PhD, MRCP, an associate professor...
Research ArticleArticles in Press109560August 07, 2026Open accessClinical outcomes of KRAS G12C versus non-G12C mutant NSCLC treated with immunotherapy: a multicentre real-world studyLaura Masfarra ∙ Ana Sofia De Freitas Matos Parreirab ∙ Natalia Castroc ∙ … ∙ Claudia Miquela ∙ Nil...
AbstractObjective The goal of the current study was to assess the frequency of KRAS mutation subtypes in a cohort of advanced non-small cell lung cancer (NSCLC). More importantly, we present the clinical characteristics, treatment profile, as well as overall survival...
